Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.53 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

35 36 Next >

BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome ↗

March 08, 2023

Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or...

Via Benzinga

Teva to Present at the Barclays Global Healthcare Conference

March 07, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Better Generics Pharmaceutical Stock: Teva or Viatris? ↗

March 05, 2023

Both have plans to return to growth.

Via The Motley Fool

Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer

March 01, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Why Teva Pharmaceutical Stock Is Sliding Today ↗

February 08, 2023

Investors were disappointed with the drugmaker's 2023 outlook.

Via The Motley Fool

Teva Pharmaceutical Stock Dives On Fourth-Quarter Miss, Light 2023 Guidance ↗

February 08, 2023

The company missed fourth-quarter estimates and issued light guidance.

Via Investor's Business Daily

7 Smart Stock Picks for Cautious Investors ↗

February 28, 2023

As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors.

Via InvestorPlace

Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026

February 27, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes

February 27, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting

February 24, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives

February 23, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday ↗

February 21, 2023

With US futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets

February 17, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap? ↗

February 17, 2023

The company's biggest moneymakers are soon to lose patent protection.

Via Investor's Business Daily

Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug ↗

February 13, 2023

Axsome Therapeutics (AXSM) stock is taking a beating on Monday as rival Teva Pharmaceutical (TEVA) prepares a generic depression drug.

Via InvestorPlace

Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling ↗

February 13, 2023

The company only just gained approval for its depression drug in August.

Via Investor's Business Daily

Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims

February 09, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Pharmaceutical Industries (TEVA) Q4 2022 Earnings Call Transcript ↗

February 08, 2023

TEVA earnings call for the period ending December 31, 2022.

Via The Motley Fool

Teva Pharma Posts Lower Q4 Earnings, FY23 Outlook Within Expectations ↗

February 08, 2023

Via Benzinga

Teva Reports Fourth Quarter and Full Year 2022 Financial Results

February 08, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Nasdaq Bear Market: 3 Tantalizing Value Stocks That Can Double Your Money by 2026 ↗

February 08, 2023

These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite.

Via The Motley Fool

The 7 Best Growth Stocks to Buy for February 2023 ↗

February 06, 2023

Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors.

Via InvestorPlace

Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review ↗

January 27, 2023

Stocks reacted well to uneven earnings and economic reports.

Via Investor's Business Daily

Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed? ↗

January 26, 2023

Things aren't as bad as they might seem.

Via The Motley Fool

6 Great Stocks to Buy in 2023 and Hold Forever ↗

January 26, 2023

I own all six great businesses and don't plan to sell a single share.

Via The Motley Fool

How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback ↗

January 25, 2023

Catalyst is adding to its portfolio with a $160 million deal.

Via Investor's Business Daily

Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025 ↗

January 25, 2023

A 33% plunge in the Nasdaq Composite is the opportune time to scoop up these exceptional deals.

Via The Motley Fool

Dow, Nasdaq Boasting Triple-Digit Midday Lead ↗

January 23, 2023

Investors seem intent on leaving last week's losses behind, as earnings season heats up.

Via Talk Markets

Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product ↗

January 23, 2023

Via Benzinga

No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product ↗

January 23, 2023

Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone.

Via Investor's Business Daily

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.